Cocrystal Development Pipeline
Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, gastroenteritis caused by norovirus, respiratory viruses, and hepatitis C.
| Program | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|---|---|---|
| Influenza A | Oral PB2 Inhibitor CC-42344 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
| Influenza A | Inhaled PB2 Inhibitor CC-42344 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase complete
|
| Influenza A/B | Replication Inhibitors |
Discovery Phase complete
|
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Norovirus & Coronavirus | Oral Pan-viral Protease Inhibitor CDI-988 |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Norovirus | Replication Inhibitors |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Respiratory Viruses | Pan-viral Inhibitors |
Discovery Phase in progress
|
Preclinical Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|